Literature DB >> 12054112

A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblasoma.

Y Inamo1, T Suzuki, H Mugishima.   

Abstract

We report an 11-year-old girl with growth failure caused by long-term administration of 13-cis-retinoic acid after bone marrow transplantation for neuroblastoma. Her growth velocity was 1-2 cm/year after 13-cis-retinoic acid administration. Her endocrinological findings were normal except for peak growth hormone levels of 6.4 ng/ml (clonidine) and 9.7 ng/ml (arginine). IGF-1 and IGFBP-3 were normal. It is not possible to conclude that her severe growth failure was caused by partial growth hormone deficiency, but premature epiphyseal closure was seen on radiographic examination. We concluded that the growth failure was caused by pediatric cancer therapy for the musculoskeletal system but not by endocrinological disturbance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12054112     DOI: 10.1507/endocrj.46.suppl_s113

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  3 in total

Review 1.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Frank Berthold
Journal:  Cochrane Database Syst Rev       Date:  2017-08-25

2.  Premature Epiphyseal Closure of the Lower Extremities Contributing to Short Stature after cis-Retinoic Acid Therapy in Medulloblastoma: A Case Report.

Authors:  Jessica J Noyes; Michael A Levine; Jean B Belasco; Sogol Mostoufi-Moab
Journal:  Horm Res Paediatr       Date:  2015-10-13       Impact factor: 2.852

3.  Correction osteotomy for bilateral varus knee deformity caused by premature epiphyseal closure induced by hypervitaminosis A: a case report.

Authors:  Masatake Matsuoka; Tomohiro Onodera; Tokifumi Majima; Koji Iwasaki; Daisuke Takahashi; Eiji Kondo; Norimasa Iwasaki
Journal:  BMC Musculoskelet Disord       Date:  2019-06-15       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.